Skip to main content
Journal ArticleOPEN ACCESS

Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

  • Fraser
  • Vogt K
  • Adachi R
  • et al.
Therapeutics and Clinical Risk Management (2011) 157
DOI: 10.2147/tcrm.s19385
N/ACitations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

The risks and benefits of continuing bisphosphonate therapy beyond 5 years in patients with primary osteoporosis have not been well established.

Cite

CITATION STYLE

APA

Fraser, Vogt, K. N., Adachi, R., & Thabane, L. (2011). Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 157. https://doi.org/10.2147/tcrm.s19385

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free